Cancer Center Clinical Trials Reporting Program (CTRP) Early Adopters

癌症中心临床试验报告计划 (CTRP) 早期采用者

基本信息

项目摘要

DESCRIPTION (provided by applicant): The Herbert Irving Comprehensive Cancer Center (HICCC) was designated an NCI Cancer Center in 1972 and gained comprehensive status in 1979. The HICCC is a component of Columbia University Medical Center and associated with New York-Presbyterian Hospital (NYPH). During the period 2003-07, CUMC and NYPH have committed over $312.7 million for i) new research initiatives in basic, clinical and population science; ii) new and expanded facilities for laboratory research and clinical activities; iii) recruitment and program restructuring; iv) support of the Center's administrative office; and v) bridge funding to offset reduced NCI CCSG support. A new Director, Riccardo Dalla-Favera, MD, was appointed in 2005 and given: i) authority over new facilities, including the Irving Cancer Research Center (ICRC), a new 10-story building dedicated to cancer research, with state-of-the-art laboratories (100,000 square feet) and incremental clinical (30,000 square feet) space in the Herbert Irving Pavilion (HIP); ii) a broad-based recruitment plan, which has already attracted 8 new faculty members to the HICCC; and iii) restructuring and expansion of the shared resources. The Director has fully reshaped the senior leadership of the HICCC with appointments of a Deputy Director for Clinical Research and Associate Directors for Basic Research, Clinical Research, Population Science, Biomedical Informatics, Shared Resources and Administration. The programmatic structure of the HICCC has been reorganized to increase cancer focus and interdisciplinary collaboration, and now includes 216 members from 22 Departments and 6 Schools, assigned to two Basic Research programs (Cancer Signaling Networks and Cancer Genetics & Epigenetics), three Disease-Specific programs (Breast Cancer, Prostate Cancer, and Lymphoid Development & Malignancy), and two Population Science programs (Cancer Epidemiology and Prevention, Control & Disparities). The HICCC administers and supports a total of 12 Shared Resources, of which four have been recently created.
描述(申请人提供):赫伯特·欧文综合癌症中心(HICCC)于1972年被指定为NCI癌症中心,并于1979年获得综合地位。HICCC是哥伦比亚大学医学中心的一个组成部分,与纽约长老会医院(NYPH)有联系。在2003-07年间,CUMC和NYPH已承诺提供超过3.127亿美元,用于i)基础、临床和人口科学方面的新研究计划;ii)实验室研究和临床活动的新设施和扩建设施;iii)招聘和计划重组;iv)对中心行政办公室的支持;以及v)用于抵消NCI CCSG减少的支持的过渡性资金。 2005年,医学博士里卡多·达拉-法维拉被任命为新主任,他被赋予:i)管理新设施的权力,包括欧文癌症研究中心(ICRC),这是一座新的10层建筑,致力于癌症研究,在赫伯特·欧文展馆(HIP)拥有最先进的实验室(10万平方英尺)和增加的临床空间(30000平方英尺);ii)基础广泛的招聘计划,该计划已经吸引了8名新的教员加入HICCC;以及iii)重组和扩大共享资源。主任通过任命一名负责临床研究的副主任和负责基础研究、临床研究、人口科学、生物医学信息学、共享资源和行政管理的副主任,彻底重塑了HICCC的高级领导层。HICCC的计划结构进行了重组,以加强癌症重点和跨学科合作,目前有来自22个部门和6所学校的216名成员,分配到两个基础研究计划(癌症信号网络和癌症遗传学与表观遗传学),三个疾病特定计划(乳腺癌、前列腺癌和淋巴发育与恶性肿瘤),以及两个人口科学计划(癌症流行病学和预防、控制与差异)。HICCC总共管理和支持12个共享资源,其中4个是最近创建的。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Riccardo Dalla-Favera其他文献

Riccardo Dalla-Favera的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Riccardo Dalla-Favera', 18)}}的其他基金

From pathogenesis to new therapeutic targets in diffuse large B cell lymphoma
弥漫性大B细胞淋巴瘤从发病机制到新的治疗靶点
  • 批准号:
    10737214
  • 财政年份:
    2023
  • 资助金额:
    $ 9.99万
  • 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
  • 批准号:
    10453790
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
MSK SPORE in Lymphoma
MSK SPORE 治疗淋巴瘤
  • 批准号:
    9753960
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
  • 批准号:
    9528531
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
  • 批准号:
    9186876
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
  • 批准号:
    9977975
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
  • 批准号:
    10224858
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
弥漫性大 B 细胞淋巴瘤从发病机制到新的治疗靶点
  • 批准号:
    9326271
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
Role of MEF2B mutations in lymphomagenesis
MEF2B 突变在淋巴瘤发生中的作用
  • 批准号:
    8697703
  • 财政年份:
    2014
  • 资助金额:
    $ 9.99万
  • 项目类别:
Role of MEF2B mutations in lymphomagenesis
MEF2B 突变在淋巴瘤发生中的作用
  • 批准号:
    8849397
  • 财政年份:
    2014
  • 资助金额:
    $ 9.99万
  • 项目类别:

相似海外基金

AI-powered digital healthcare platform that delivers health benefits to Bengali speakers in the UK through voice-driven remote medical triaging, appointment booking and self-care at home.
由人工智能驱动的数字医疗平台,通过语音驱动的远程医疗分类、预约和在家自我护理,为英国的孟加拉语使用者提供健康益处。
  • 批准号:
    10043942
  • 财政年份:
    2022
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Grant for R&D
NHS Appointment Recovery Project
NHS 预约恢复项目
  • 批准号:
    62930
  • 财政年份:
    2020
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Feasibility Studies
An Innovative, Automated, Machine Learning Appointment, Logistics and Communication Platform for Mobile Service Provider SMEs that can incorporate
为移动服务提供商中小企业提供创新、自动化、机器学习预约、物流和通信平台,可将
  • 批准号:
    86195
  • 财政年份:
    2020
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Collaborative R&D
Factors Promoting and Inhibiting the Appointment of Women in the Public Sector
促进和抑制妇女在公共部门任职的因素
  • 批准号:
    20H01456
  • 财政年份:
    2020
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (B)
A Primary Care Online Appointment Scheduling Platform for Emergency Departments: Improving the Care Transition between Emergency and Primary Care
急诊科初级保健在线预约安排平台:改善急诊和初级保健之间的护理过渡
  • 批准号:
    382187
  • 财政年份:
    2018
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Operating Grants
Appointment of Supreme Court Justices and Formation of Judicial Precedents
最高法院法官的任命和判例的形成
  • 批准号:
    18K01395
  • 财政年份:
    2018
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Quantitative network analysis of appointment diaries
预约日记的定量网络分析
  • 批准号:
    ES/R009236/1
  • 财政年份:
    2018
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Research Grant
A Study on the Process of Appointment of Principal by Physical Education Teachers and Formation of Management Competence
体育教师校长聘任过程与管理能力形成研究
  • 批准号:
    16K16538
  • 财政年份:
    2016
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Reconstruction of the history of Japanese education through historical clarification of the transition between education at "daigaku" and appointment of government officials in ancient Japan
通过历史澄清古代日本“大学”教育与政府官员任用之间的转变,重建日本教育史
  • 批准号:
    15K17374
  • 财政年份:
    2015
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Grant-in-Aid for Young Scientists (B)
Appointment Provisioning/Booking Platform
预约提供/预订平台
  • 批准号:
    486943-2015
  • 财政年份:
    2015
  • 资助金额:
    $ 9.99万
  • 项目类别:
    Experience Awards (previously Industrial Undergraduate Student Research Awards)
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了